Status:
COMPLETED
Epidemiology of Bacteremia at Two Tertiary ICUs in Switzerland
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Conditions:
Bacteremia
Eligibility:
All Genders
18+ years
Brief Summary
The objectives of the retrospective cohort study is to describe the actual current practice of antibiotic treatment duration for bloodstream infections in critically ill patients at two tertiary hospi...
Eligibility Criteria
Inclusion
- Patient has a positive blood culture with a pathogenic organism Patient is critically ill at the time the blood culture was collected as defined by the following:
- was treated at the ICU/IMC at the time of blood culture collection;
- or has been admitted to ICU/IMC in the 48 hours after blood culture collection
Exclusion
- Patient has a single positive blood culture with a common contaminant organism:
- coagulase negative staphylococci;
- Bacillus spp.;
- Corynebacterium spp.;
- Propionibacterium spp.;
- Aerococcus spp.;
- Micrococcus spp.
- Explicit documentation that the patient does not want to participate in any study
Key Trial Info
Start Date :
February 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 30 2022
Estimated Enrollment :
395 Patients enrolled
Trial Details
Trial ID
NCT05236283
Start Date
February 1 2022
End Date
March 30 2022
Last Update
January 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Departement of Intensive Care Medicine
Bern, Switzerland